4.3 Review

Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease

Journal

CLINICAL NEUROLOGY AND NEUROSURGERY
Volume 107, Issue 5, Pages 355-360

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.clineuro.2004.12.002

Keywords

prion disease; 14-3-3 protein; tau protein; amyloid-beta; variant CJD; sporadic CJD; differential diagnosis

Ask authors/readers for more resources

Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative disorder. Since the emergence of variant CID (vCJD) vigilance concerning the disease's incidence has increased and the interest in accurate in vivo diagnosis has augmented. So far, a large number of biomarkers has been investigated as aid in the differential diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) and vCJD. These include, among others, neuron-specific enolase (NSE), microtubuli associated protein Tau, S-100 beta, amyloid-beta (A beta(1-42)) and the 14-3-3 protein. Multiple studies have confirmed that CSF detection of 14-3-3 protein by Western blot was the best single biomarker for sCJD with an average sensitivity and specificity of 92%. Also, in genetic and iatrogenic CJD (iCJD) patients with an average disease duration of less than 1 year, 14-3-3 is the best differential biomarker. Unfortunately, the 14-3-3 protein has a lower sensitivity if the disease duration exceeds beyond I year in both sporadic CID and other CJD types (vCJD, and specific genetic or iatrogenic CJD types). (c) 2004 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available